Home > Insider Trading > Filing (0001140361-14-023855)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1594337	Corium International Inc.	CORI	Pharmaceutical Preparations (2834)	383230774

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1271088	D Peter Staple	C/O Corium International, Inc. 235 Constitution Drive Menlo Park CA 94025	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-05-28	1,900	$6.95	1,900	No	4	P	Indirect	by The Staple Family 2006 Trust
Common Stock	Acquisiton	2014-05-29	2,900	$7.08	4,800	No	4	P	Indirect	by The Staple Family 2006 Trust
Common Stock	Acquisiton	2014-05-30	2,400	$7.08	7,200	No	4	P	Indirect	by The Staple Family 2006 Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	by The Staple Family 2006 Trust
No	4	P	Indirect	by The Staple Family 2006 Trust
No	4	P	Indirect	by The Staple Family 2006 Trust

Footnotes

Represents the aggregate of purchases effected on the same day at different prices.
Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $6.85 to $6.995. Full information regarding the number of shares purchased at each price shall be provided, upon written request, to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $6.980 to $7.100. Full information regarding the number of shares purchased at each price shall be provided, upon written request, to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $6.89 to $7.15. Full information regarding the number of shares purchased at each price shall be provided, upon written request, to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.